000 | 01988 a2200505 4500 | ||
---|---|---|---|
005 | 20250516122100.0 | ||
264 | 0 | _c20130620 | |
008 | 201306s 0 0 eng d | ||
022 | _a1741-0134 | ||
024 | 7 |
_a10.1093/protein/gzs094 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aMattis, D M | |
245 | 0 | 0 |
_aEngineering a soluble high-affinity receptor domain that neutralizes staphylococcal enterotoxin C in rabbit models of disease. _h[electronic resource] |
260 |
_bProtein engineering, design & selection : PEDS _cFeb 2013 |
||
300 |
_a133-42 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 | _aAnimals |
650 | 0 | 4 |
_aAnti-Bacterial Agents _xadministration & dosage |
650 | 0 | 4 | _aCell Line |
650 | 0 | 4 | _aCell Surface Display Techniques |
650 | 0 | 4 | _aDirected Molecular Evolution |
650 | 0 | 4 | _aDisease Models, Animal |
650 | 0 | 4 |
_aEndocarditis, Bacterial _xdrug therapy |
650 | 0 | 4 |
_aEnterotoxins _xantagonists & inhibitors |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aInterleukin-2 _xmetabolism |
650 | 0 | 4 | _aLymphocyte Activation |
650 | 0 | 4 |
_aMethicillin-Resistant Staphylococcus aureus _ximmunology |
650 | 0 | 4 |
_aPneumonia, Staphylococcal _xdrug therapy |
650 | 0 | 4 | _aProtein Binding |
650 | 0 | 4 | _aProtein Engineering |
650 | 0 | 4 | _aRabbits |
650 | 0 | 4 |
_aReceptors, Antigen, T-Cell, alpha-beta _xadministration & dosage |
650 | 0 | 4 |
_aRecombinant Proteins _xadministration & dosage |
650 | 0 | 4 |
_aStaphylococcal Infections _xdrug therapy |
650 | 0 | 4 |
_aSuperantigens _xmetabolism |
650 | 0 | 4 |
_aT-Lymphocytes _xdrug effects |
700 | 1 | _aSpaulding, A R | |
700 | 1 | _aChuang-Smith, O N | |
700 | 1 | _aSundberg, E J | |
700 | 1 | _aSchlievert, P M | |
700 | 1 | _aKranz, D M | |
773 | 0 |
_tProtein engineering, design & selection : PEDS _gvol. 26 _gno. 2 _gp. 133-42 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1093/protein/gzs094 _zAvailable from publisher's website |
999 |
_c22273626 _d22273626 |